Finally, there are novel therapeutic agents including the once-daily androgen receptor signaling inhibitor enzalutamide, previously called MDV3100 [32, 33] (Figure 3), which significantly prolonged overall survival in a randomized phase III trial that involved 1,199 men with castration-resistant prostate cancer [34]. Here, AR is linked to prostate carcinoma.